rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

R-miniCHOP is a reduced-intensity chemoimmunotherapy regimen specifically designed for the treatment of older or frail patients with diffuse large B-cell lymphoma (DLBCL). It is an attenuated version of the standard R-CHOP regimen, consisting of a full dose of the anti-CD20 monoclonal antibody rituximab combined with approximately 50% of the standard doses of the CHOP chemotherapy components: cyclophosphamide, doxorubicin (hydroxydaunorubicin), and vincristine (Oncovin), along with prednisone. This modification aims to maintain curative intent while minimizing severe toxicities, such as myelosuppression and cardiotoxicity, in patients aged 80 years and older or those with significant age-related comorbidities. Clinical data from registries like LEO and GELL support R-miniCHOP as a viable frontline alternative to full-dose R-CHOP in vulnerable populations, offering comparable overall survival with a more manageable safety profile.

Other names

R-miniCHOPreduced-dose R-CHOPattenuated R-CHOP